Covid 19 Research using Clinical Trials (Home Page)
HP:0002293: Alopecia of scalpHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug227 | CAG length >=24 Wiki | 1.00 |
| drug1390 | Throat swab Wiki | 1.00 |
| drug226 | CAG length <24 Wiki | 1.00 |
| drug211 | Blood sampling Wiki | 0.58 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess the risk of developing severe symptoms following COVID-19 infection, The COVID-19 Androgen Sensitivity Test requires a health care professional to collect a DNA sample using an FDA cleared DNA sample collection kit.
NCT04368897 SARS-CoV 2 COVID COVID-19 Androgenetic Alopecia Androgen Receptor Abnormal Androgen Deficiency Diagnostic Test: CAG length <24 Diagnostic Test: CAG length >=24 MeSH:Alopecia
HPO:Alopecia Alopecia of scalp Frontal balding
Primary Outcomes
Description: Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.
Measure: Hospital-free days to Day 28 [ Time Frame: 28 days] Time: 28 days
Description: Defined as discharged, hospitalization, admission to intensive care unit [ICU] and death
Measure: 1. Severity of Disease Time: Day 28
HPO Nodes
Primary Outcomes
Description: Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.
Measure: Hospital-free days to Day 28 [ Time Frame: 28 days] Time: 28 daysDescription: Defined as discharged, hospitalization, admission to intensive care unit [ICU] and death
Measure: 1. Severity of Disease Time: Day 28